Substance use disorders (SUDs) in oncology populations represent a significant yet underrecognized challenge, with prior research suggesting that up to 27 percent of cancer patients meet criteria for ...

The glucagon-like peptide 1 (GLP-1) receptor agonist semaglutide has made headlines as a US Food and Drug Administration (FDA)–approved treatment for type 2 diabetes (Ozempic) and obesity (Wegovy).

Adial Pharmaceuticals has announced the issuance of patent number 12,226,401, which enhances their genetic-based approach for treating alcohol and opioid use disorders. This new patent focuses on ...

This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they ...

Please provide your email address to receive an email when new articles are posted on . At 12 months, 7.1% of patients with AUD and cirrhosis in the naltrexone group vs. 28.6% in the placebo group had ...